Investor Relations

about us page title image

Investor Relations

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, maximising insights to identify, develop, formulate and commercialise cutting-edge antimicrobial technologies delivered in direct sales and in long-term licensing partnerships with consumer and professional multi-nationals.

Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens.

Issued Share Capital

  • 21.20%
    Ruffer
    (56,818,121)
  • 7.66%
    Walker Crips
    (20,542,800)
  • 5.62%
    Fiske
    (15,071,083)
  • 3.73%
    Mr C Wallace
    (10,000,000)
  • 4.08%
    Hargreaves Lansdown
    (10,935,435)
  • 7.85%
    Maunby Investment Management
    (21,049,180)
  • 5.45%
    Bricon Byotrol
    (14,599,038)
  • 5.11%
    ?WhatIf! Holdings
    (13,689,569)
  • The company’s share: 0.25p each

  • Total issued shares capital: 268,051,565

  • Number of shares (if any) held in treasury: Nil

Pursuant to the AIM Rules, and insofar as the Company is aware, as at 5/12/16, 66,043,361 of the Company's AIM securities were not in public hands.

There are no restrictions on the transfer of the ordinary shares in the capital of the company. The Company is subject to the UK City Code on Takeovers and Mergers.

Last updated 14th December 2016

Top News

Last updated 14th December 2016